2021
DOI: 10.3390/cancers13164005
|View full text |Cite
|
Sign up to set email alerts
|

The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling

Abstract: Response rates to the current gold standards of care for treating oesophageal adenocarcinoma (OAC) remain modest with 15–25% of patients achieving meaningful pathological responses, highlighting the need for novel therapeutic strategies. This study consists of immune, angiogenic, and inflammatory profiling of the tumour microenvironment (TME) and lymph node microenvironment (LNME) in OAC. The prognostic value of nodal involvement and clinicopathological features was compared using a retrospective cohort of OAC… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

3
3

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 45 publications
0
2
0
Order By: Relevance
“…OAC patient-derived tumour-conditioned media (TCM) was generated as previously described [30]. OAC tumour explants of ~2-3 mm 3 were transferred into 1 mL of serumfree M199 media (Gibco, Billings, MT, USA), supplemented with gentamicin in a 12-well plate.…”
Section: Generation Of Tumour-conditioned Mediamentioning
confidence: 99%
“…OAC patient-derived tumour-conditioned media (TCM) was generated as previously described [30]. OAC tumour explants of ~2-3 mm 3 were transferred into 1 mL of serumfree M199 media (Gibco, Billings, MT, USA), supplemented with gentamicin in a 12-well plate.…”
Section: Generation Of Tumour-conditioned Mediamentioning
confidence: 99%
“…The burden of OAC is expected to rise dramatically and surpass oesophageal squamous cell carcinoma, in high-income countries by 2020 [3], with an accompanying rise in the number of patients seeking treatment. Curative therapy consists of surgery, either alone or in combination with adjuvant or neo-adjuvant chemotherapy or radiation, or combination chemoradiotherapy regimens (neo-CRT) [4,5]. However, only a minority of patients respond to such treatments, meaning the majority (70-80%) of patients will experience treatment-related toxicity and delay to surgery with no clinical benefit [6,7].…”
Section: Introductionmentioning
confidence: 99%